The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation

European Journal of Pediatrics
Albert DirisamerKurt Widhalm

Abstract

Familial hypercholesterolaemia (FH) is a severe disorder of lipid metabolism associated with an enhanced risk to develop cardiovascular disease later in life, with atherosclerotic lesions beginning already in childhood. These are facts which make an early diagnosis and therapy necessary to prevent or delay such complications. The aim of this study was to investigate the efficacy and safety of low-dose simvastatin, a potent HMG-CoA reductase inhibitor, in children and adolescents with FH. Therefore, 20 children and adolescents (12 females, 8 males) aged between 10 and 17 years with FH were recruited for this 1-year simvastatin study. According to baseline levels of low density lipoprotein (LDL)-C, girls and boys were divided into two groups, one group (with LDL-C <220 mg/dl) starting with a simvastatin dosage of 5 mg/day, the other (with LDL-C >220 mg/dl) 10 mg/day with the possibility to increase dosages up to a daily maximum of 20 mg, if not reaching LDL-C concentrations of <170 mg/dl within the first period. Every 4-8 weeks, weight, height, lipids, Lp(a) and routine safety parameters of all participants were determined by a paediatrician, documenting exactly all side-effects. The percentage decrease was 25% for LDL-C in the 5...Continue Reading

References

Jun 13, 1992·Lancet·J DucobuM Thomson
Jan 23, 1999·JAMA : the Journal of the American Medical Association·E A SteinG J Gormley

❮ Previous
Next ❯

Citations

Apr 23, 2004·Archives of Disease in Childhood·T Reinehr, W Andler
Jan 1, 2011·BMJ Case Reports·Michelle FungJiri Frohlich
Nov 8, 2019·The Cochrane Database of Systematic Reviews·Alpo VuorioUma Ramaswami
Nov 1, 2005·Current Cardiology Reports·Kathryn Wood Holmes, Peter Oscar Kwiterovich
Jul 10, 2004·Current Opinion in Lipidology·J RodenburgJohn J P Kastelein
Jul 27, 2004·Current Opinion in Pediatrics·Michael Kohn, Marc S Jacobson
Oct 13, 2006·Journal of Pediatric Gastroenterology and Nutrition·Thomas ReinehrMartin Wabitsch
Apr 20, 2010·Expert Review of Cardiovascular Therapy·Fernanda Luisa Ceragioli OliveiraMaria Arlete Meil Schimith Escrivão
Jun 11, 2016·The Journal of Clinical Endocrinology and Metabolism·Thomas ReinehrReinhard W Holl
Jan 1, 2011·The Journal of Cardiovascular Nursing·Debra A Robbins
May 24, 2016·Expert Opinion on Drug Delivery·Alaa S TulbahDaniela Traini
Nov 24, 2016·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Jonathan Wagner, Susan M Abdel-Rahman
Apr 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
Sep 1, 2008·Expert Review of Endocrinology & Metabolism·Lorenzo IughettiFiorella Balli
Mar 30, 2005·Expert Opinion on Drug Safety·Rodrigo AlonsoPedro Mata
Jul 8, 2017·The Cochrane Database of Systematic Reviews·Alpo VuorioUma Ramaswami
Sep 9, 2006·The American Journal of Clinical Nutrition·Thomas ReinehrWerner Andler
Dec 15, 2018·Clinical Pharmacology and Therapeutics·Jonathan B WagnerJ Steven Leeder
Dec 22, 2020·Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners·Sarah Dombalis, Angela Nash

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.